Netherlands· NL-f8505473f0b9
Lumykras 120 mg, filmomhulde tablet
A sotorasib product containing sotorasib, registered in Netherlands by Amgen Europe B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sotorasib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX73 (sotorasib), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Sotorasib · ATC L01XX73
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SOTORASIB
- Manufacturer
- Amgen Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- L01XX73
- ATC class
- Sotorasib
- Defined daily dose
- 0.96 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1603
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sotorasib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLUMYKRASAmgen Europe B.V., Breda
- FinlandLUMYKRASAbacus Medicine A/S
- FranceLUMYKRAS 120 mg, comprimé pelliculéAMGEN EUROPE
- IrelandLUMYKRAS 120 mg film-coated tabletsAmgen Europe B.V.,
- IcelandLumykrasAmgen Europe B.V.*
- NorwayLumykrasAmgen Europe B.V. (2)
- PolandLumykrasAmgen Europe B.V.
- BelgiumLumykras 120 mgAmgen Europe
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Lumykras
- Norway · Lumykras
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ffc561b6-d7ad-46b2-ad14-388fdb1f603b GET /v1/drugs/ffc561b6-d7ad-46b2-ad14-388fdb1f603b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sotorasib",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127806",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"IJZEROXIDE GEEL (E 172)",
"LACTOSE 1-WATER",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"SOTORASIB"
],
"leaflet_url": null,
"authorised_at": "2022/01/06",
"procedure_number": "EMEA/H/C/005522",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1603",
"additional_monitoring": "Y"
}See everything about sotorasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.